Q2 2025 Earnings

Revenue

$9M+17.3% YoY

Gross Profit

$6M60.3% margin

Operating Income

-$6M-61.6% margin

Net Income

-$6M-63.3% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+8.6%

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Total Assets

$63M

Total Liabilities

$43M

Stockholders' Equity

$20M

Cash & Equivalents

$42M

Metric	Current	Year Ago	Change
Revenue	$9M	$8M	+17.3%
Gross Profit	$6M	$5M	+11.4%
Operating Income	-$6M	-$5M	-19.9%
Net Income	-$6M	-$4M	-32.4%

Biologics And Drug Delivery

$5M54%

Biologics And Drug Delivery - Disposable Products

$2M22%

Capital Equipment And Software

$1M12%

Capital Equipment And Software - Systems and Software Products

$694,0008%

Capital Equipment And Software - Services

$350,0004%